Akari Therapeutics (AKTX) Registration filing summary

Company overview and business model

• Focuses on developing next-generation antibody-drug conjugates (ADCs) using proprietary cancer-killing toxins as payloads, aiming to improve efficacy and safety over current ADC therapies.

• Lead product candidate, AKTX-101, targets Trop2 in solid tumors and is in preclinical development, with a Phase 1 trial planned by mid-2027.

• Pipeline includes AKTX-102, a CEACAM5-directed ADC, leveraging the same novel payload platform.

• No commercial products or product revenue to date; business activities have focused on R&D and capital raising.

Financial performance and metrics

• Has a history of operating losses and has not generated product revenue.

• Ongoing operations depend on raising substantial additional capital for R&D and infrastructure.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of ADSs by selling shareholders; proceeds from warrant exercises (if any, up to $16.5 million) will be used for R&D, general/admin expenses, and working capital.

• Pending use, proceeds will be invested in short-term, interest-bearing, investment-grade securities.